---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021217"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:12:36.010163+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23

## Summary
- Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.
- Cash, equivalents, and short-term investments totaled $93.8M as of March 31, 2023.
- Completed enrollment of pivotal STRIDE study (213 patients); topline results expected Q4 2023.
- Raised $68.3M gross from public offering and private placement in May 2023.
- Received FDA Fast Track designation for mavodelpar in long-chain fatty acid oxidation disorder.

## SEC filing metadata
- accession: 0000950170-23-021217
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/0000950170-23-021217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/rphm-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021217
- JSON: https://secwatch.observer/filing/0000950170-23-021217.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021217.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $15.1 million, EPS $0.60 per share.
  - Period: the quarter ended March 31, 2023
  - Net income: net loss of $15.1 million
  - EPS: $0.60 per share
  - Result: reported results
  source text: We reported a net loss of $15.1 million, or $0.60 per share, during the first quarter of 2023, compared to a net loss of $13.0 million, or $0.53 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/0000950170-23-021217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.